Measures the incidence/severity of fatigue for renal cancer patients
Research type
Research Study
Full title
A study to measure the incidence and severity of fatigue in renal cancer patients receiving pazopanib (Votrient®)or sunitinib (Sutent®).
IRAS ID
153491
Contact name
Waleed Altowayan
Contact email
Sponsor organisation
Contracts Manager Research & Knowledge Exchange Services University of Strathclyde
Duration of Study in the UK
0 years, 11 months, 30 days
Research summary
Fatigue is one of the most common side effects for tyrosine kinase inhibitor (TKI) medications (sunitinib and pazopanib) that have been recently licensed in the United Kingdom as a first line treatment for metastatic renal cancer patients. Therefore, the aim of the proposed research is to accurately assess fatigue and to develop a simple fatigue measurement tool for evaluation in renal cancer patients undergoing treatment with TKIs. As fatigue may be influenced by many factors that may negatively impact on the incidence and/or severity of fatigue, this research will further examine these confounding factors and examine if there is a correlation between individual patient’s fatigue scores and cancer symptoms. A further aim is to assess any potential impact of TKI medications may have on the life style of renal cancer patients. This study is which is being undertaken in collaboration with Beatson West of Scotland Cancer Centre is aiming to include 80 patients with metastatic renal cell carcinoma (RCC) who are treated with the TKIs sunitinib or pazopanib at the Beatson West of Scotland cancer centre, Glasgow regardless of the disease histology or prior treatment for renal cancer. Patient will be evaluated using the Functional Assessment Chronic Illness Therapy-Fatigue (FACIT-F) and The M. D. Anderson Symptom Inventory (MDASI) tools.Each participant will complete a new copy of each questionnaire during their visits to the clinic for four consecutive treatment cycles starting on the day they join the study.
REC name
London - South East Research Ethics Committee
REC reference
14/LO/2135
Date of REC Opinion
25 Nov 2014
REC opinion
Favourable Opinion